Impact of P2Y12 inhibitor pretreatment on periprocedural (type 4a) myocardial infarction and bleeding in NSTEMI
{{output}}
Introduction and objectives: Although widely used in clinical practice, pretreatment with a P2Y12 inhibitor in patients with non-ST-segment elevation myocardial infarction (NSTEMI) remains controversial and is not recommended by ... ...
